

Bezlotoxumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024
1.19 28.09.2024 809032-00020 Date of first issue: 22.07.2016

Section 1: Identification

Product identifier : Bezlotoxumab Formulation

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

Manufacturer or supplier's details

Company : MSD

Address : 50 Tuas West Drive

Singapore - Singapore 638408

Telephone : +1-908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

Section 2: Hazard identification

Classification of the substance or mixture

Not a hazardous substance or mixture.

GHS Label elements, including precautionary statements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|---------------|--------------|-----------------------|
| Bezlotoxumab | 1246264-45-8 | >= 1 -< 10 |

Section 4: First-aid measures

Description of necessary first-aid measures

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.



Bezlotoxumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.19 28.09.2024 809032-00020 Date of first issue: 22.07.2016

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed

Risks : None known.

Protection of first-aiders : No special precautions are necessary for first aid responders.

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Special protective actions for fire-fighters

Special protective equipment :

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures

Personal precautions : Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).



Bezlotoxumab Formulation

SDS Number: Date of last issue: 06.04.2024 Version Revision Date: 1.19 28.09.2024 809032-00020 Date of first issue: 22.07.2016

Environmental precautions

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material. Methods for cleaning up

> For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

Section 7: Handling and storage

Precautions for safe handling

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage, including any incompatibilities

Conditions for safe storage Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Do not store with the following product types: Materials to avoid

Strong oxidizing agents



Bezlotoxumab Formulation

SDS Number: Date of last issue: 06.04.2024 Version Revision Date: 1.19 28.09.2024 809032-00020 Date of first issue: 22.07.2016

Section 8: Exposure controls/personal protection

Control parameters

Occupational Exposure Limits

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--------------|------------------|-------------------------------------|--|----------|
| Bezlotoxumab | 1246264-45- 8 | TWA | 5.0 mg/m3 (OEB 1) | Internal |

Appropriate engineering control measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Work uniform or laboratory coat. Skin protection

If adequate local exhaust ventilation is not available or expo-Respiratory protection

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Hand protection

Particulates type

Material Chemical-resistant gloves

Section 9: Physical and chemical properties

Appearance Aqueous solution

Colour Colorless to pale yellow

Odour No data available

Odour Threshold No data available

5.7 - 6.3pН

Melting point/freezing point No data available



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.19
 28.09.2024
 809032-00020
 Date of first issue: 22.07.2016

Initial boiling point and boiling :

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1.0146 g/cm³

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : 1.2 mPa.s (25 °C)

Viscosity, kinematic : 1.833 mm2/s (4 °C)

1.183 mm2/s (25 °C)

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

Section 10: Stability and reactivity



Bezlotoxumab Formulation

Revision Date: SDS Number: Date of last issue: 06.04.2024 Version 1.19 28.09.2024 809032-00020 Date of first issue: 22.07.2016

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions. Can react with strong oxidizing agents.

Possibility of hazardous reac-

None known.

Conditions to avoid Incompatible materials Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of: Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Bezlotoxumab:

Acute toxicity (other routes of : LD50 (Mouse): > 125 mg/kg

administration) Application Route: Intravenous

Remarks: No adverse effect has been observed in acute tox-

icity tests.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

STOT - single exposure

Not classified based on available information.



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.19
 28.09.2024
 809032-00020
 Date of first issue: 22.07.2016

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Bezlotoxumab:

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Intravenous

Exposure time : 15 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 125 mg/kg
Application Route : Intravenous

Exposure time : 21 d

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Bezlotoxumab:

Inhalation : Symptoms: Nausea, Headache, Diarrhoea, Fever

Section 12: Ecological information

Toxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.



Bezlotoxumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.19 28.09.2024 809032-00020 Date of first issue: 22.07.2016

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG

UN number : Not applicable
UN proper shipping name : Not applicable
Transport hazard class(es) : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
UN proper shipping name : Not applicable
Transport hazard class(es) : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen: Not applicable

ger aircraft)

IMDG-Code

UN number Not applicable Not applicable UN proper shipping name Not applicable Transport hazard class(es) Not applicable Subsidiary risk Packing group Not applicable Labels Not applicable **EmS Code** Not applicable Not applicable Marine pollutant

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.19
 28.09.2024
 809032-00020
 Date of first issue: 22.07.2016

Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable

Regulations

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 28.09.2024

Further information

Sources of key data used to

compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association: IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evalua-



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.19
 28.09.2024
 809032-00020
 Date of first issue: 22.07.2016

tion, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN